The impact of PCCM on healthcare among asthma or Chronic obstructive pulmonary disease (COPD) or Asthma-COPD overlap patients

Trial Identifier:	D589BR00066
Sponsor:	AstraZeneca
NCTID::	NCT04905420
Start Date:	December 2021
Primary Completion Date:	June 2023
Study Completion Date:	June 2023
Condition:	Asthma; Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Tianjin, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.